Scientific Program
DATE/TIME: December 6, 9:30 – 10:45 A.M.
PRESENTATION TITLE:
Dissecting enhancer function in hematopoietic development and disease
LOCATION: OCCC - W312
ACOMMITTEE: Scientific Committee on Epigenetics and Genomics
SPEAKER: Martin Rivas, Ph.D., M.S.
Oral Presentations
DATE/TIME: December 6, 12:45 – 1:00 P.M.
PRESENTATION TITLE:
Loss of p53 Enhances LMO2 Induced Transdifferentiation of B-cells to T-cell Acute Lymphoblastic Leukemia
LOCATION: OCCC - W224ABEF
ABSTRACT #: 142 abs25-4663
FIRST AND PRESENTING AUTHOR: Izidore S. Lossos, M.D.
LAST AUTHOR: Daniel Bilbao, Ph.D., M.B.A.
DATE/TIME: December 6, 2:15 – 2:30 P.M.
PRESENTATION TITLE:
A Phase 2 Trial of Abbreviated Fixed-Duration (Default 4 Cycles) Linvoseltamab Immuno-Consolidation to Deepen Responses Post Newly Diagnosed Multiple Myeloma Combination Therapy for Minimal Residual Disease Positivity (the IMMUNOPLANT Study)
LOCATION: OCCC - West Hall D1
ABSTRACT #: 248 abs25-8386
FIRST AND PRESENTING AUTHOR: Dickran Kazandjian, M.D.
LAST AUTHOR: C. Ola Landgren, M.D., Ph.D.
DATE/TIME: December 6, 2:45 – 3:00 P.M.
PRESENTATION TITLE:
Clinical Translation of Single Cell Measurable Residual Disease (scMRD) Assay in Real World Acute Myeloid Leukemia (AML) Patients
LOCATION: Hyatt - Regency Ballroom R
ABSTRACT #: 280 abs25-9565
FIRST AND PRESENTING AUTHOR: Katarina Micin, M.S.
DATE/TIME: December 6, 3:00 – 3:15 P.M.
PRESENTATION TITLE:
A Phase 2 Trial of Iberdomide, Carfilzomib, Daratumumab and Dexamethasone Quadruplet Therapy for Relapsed/Refractory Multiple Myeloma: The Rekindle Study
LOCATION: OCCC - West Hall D1
ABSTRACT #: 251 abs25-4108
FIRST AUTHOR: C. Ola Landgren, M.D., Ph.D.
LAST AND PRESENTING AUTHOR: Benjamin Diamond, M.D.
Poster Presentations
DATE/TIME: December 6, 5:30 – 7:30 P.M.
LOCATION: OCCC - West Halls B3-B4
PRESENTATION TITLE:
Monoclonal Gammopathy-Related Coagulopathies: A Systematic Analysis
ABSTRACT #: 1305 abs25-8382
FIRST AND PRESENTING AUTHOR: Tessa Lavorgna, M.D.
PRESENTATION TITLE:
Direct Thrombin Inhibition by Paraprotein in Multiple Myeloma: A Rare Mechanism of Paraprotein-Mediated Coagulopathy, Corrected with Myeloma Therapy
ABSTRACT #: 1306 abs25-8483
FIRST AND PRESENTING AUTHOR: Tessa Lavorgna, M.D.
PRESENTATION TITLE:
Results of the Phase 1B Study of Pegargiminase (ADI-PEG 20) in Combination with AZA-VEN in Newly Diagnosed High-Risk AML Patients Not Candidates for Intensive Chemotherapy
ABSTRACT #: 1650 abs25-14758
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
PRESENTATION TITLE:
Clinical Characteristics and Response in Olutasidenib-Treated Relapsed/Refractory mIDH1 Acute Myeloid Leukemia (AML) Patients with Stable Disease Following Two Treatment Cycles
ABSTRACT #: 1659 abs25-1541
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
PRESENTATION TITLE:
Genomic and Transcriptomic Landscape of Extranodal Marginal Zone Lymphoma
ABSTRACT #: 1761 abs25-9990
FIRST AND PRESENTING AUTHOR: Izidore S. Lossos, M.D.
LAST AUTHOR: Jennifer Chapman, M.D.
PRESENTATION TITLE:
A Genetic Comparison of Epstein-Barr Virus-Associated Polymorphic Lymphoproliferative Disorder and Diffuse Large B Cell Lymphoma
ABSTRACT #: 1776 abs25-2692
FIRST AND PRESENTING AUTHOR: Jennifer Chapman, M.D.
LAST AUTHOR: Izidore S. Lossos, M.D.
PRESENTATION TITLE:
A Phase 2 Study with Tafasitamab and Zanubrutinib in Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma – Taza CLL
ABSTRACT #: 2134 abs25-14355
FIRST AND PRESENTING AUTHOR: Georgios Pongas, M.D.
PRESENTATION TITLE:
Single-Cell DNA Sequencing Uncovers Synergistic Co-Mutations in Multiple Myeloma
ABSTRACT #: 2157 abs25-10230
FIRST AND PRESENTING AUTHOR: Ava Amidei, B.S.
LAST AUTHOR: David G. Coffey, M.D.
Special Sessions
DATE/TIME: December 7, 9:30 – 11:00 A.M.
PRESENTATION TITLE:
Updated ASH Clinical Practice Guidelines on Acute Myeloid Leukemia (AML) in Older Adults
LOCATION: OCCC - W414CD
ABSTRACT #: Special Interest Session
FIRST AND PRESENTING AUTHOR: Mikkael A. Sekeres, M.D., M.S.
Oral Presentations
DATE/TIME: December 7, 1:00 – 1:15 P.M.
PRESENTATION TITLE:
A Phase 2 Trial of AI-BEL (AZT/Interferon-α Plus Belinostat) for HTLV-1 Related Adult T-cell Leukemia-Lymphoma: Final Safety and Efficacy Results
LOCATION: OCCC - Tangerine Ballroom F2
ABSTRACT #: 563 abs25-14380
FIRST AUTHOR: Georgios Pongas, M.D.
PRESENTING AUTHOR: Juan Carlos Ramos, M.D.
Poster Presentations
DATE/TIME: December 7, 6:00 – 8:00 P.M.
LOCATION: OCCC - West Halls B3-B4
PRESENTATION TITLE:
A Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the Predict Study
ABSTRACT #: 3067 abs25-8287
FIRST AND PRESENTING AUTHOR: Fernando Corrales-Medina, M.D.
PRESENTATION TITLE:
Butyrate Ameliorates Tet2-Deficient Clonal Hematopoiesis Phenotypes Driven by High B12-Induced Gut Dysbiosis
ABSTRACT #: 3173 abs25-13748
FIRST AND PRESENTING AUTHOR: John Brabson, M.S.
LAST AUTHOR: Luisa Cimmino, Ph.D.
PRESENTATION TITLE:
Vitamin B12 Drives Epigenetic Reprogramming and Leukemia Progression Through Metabolic Rewiring in AML
ABSTRACT #: 3250 abs25-15145
FIRST AND PRESENTING AUTHOR: Peter Lyon
PRESENTATION TITLE:
Synergistic Targeting of KMT2A-Rearranged AML with Combined LSD1 and Menin Inhibitors
ABSTRACT #: 3292 abs25-13831
FIRST AND PRESENTING AUTHOR: Mina Tayari, Ph.D.
LAST AUTHOR: Justin M. Watts, M.D.
PRESENTATION TITLE:
Characterizing the Biological Function FOXO3 and Its Role as a Predictive Biomarker in HTLV-1 Related Adult T-cell Leukemia-Lymphoma
ABSTRACT #: 3546 abs25-15291
FIRST AND PRESENTING AUTHOR: Georgios Pongas, M.D.
LAST AUTHOR: Juan Carlos Ramos, M.D.
PRESENTATION TITLE:
Real-World Effectiveness and Safety Outcomes by Age, Comorbidities, and Frailty Among Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL) Patients Treated with Brexucabtagene Autoleucel (Brexu-cel)
ABSTRACT #: 3606 abs25-13334
FIRST AND PRESENTING AUTHOR: Amer M. Beitinjaneh, M.D.
PRESENTATION TITLE:
Frontline Chemotherapy for CD30+ Non-ALCL Peripheral T-cell Lymphoma: A Multi-Center Retrospective Analysis
ABSTRACT #: 3641 abs25-8852
FIRST AND PRESENTING AUTHOR: Asaad Trabolsi, M.D.
LAST AUTHOR: Jonathan H. Schatz, M.D.
PRESENTATION TITLE:
Whole Genome Sequencing of Cell-Free DNA for Assessment of Minimal Residual Disease in High-Risk Smoldering Multiple Myeloma
ABSTRACT #: 3920 abs25-4528
FIRST AUTHOR: Chrissy Baker
PRESENTING AUTHOR: Benjamin Diamond, M.D.
PRESENTATION TITLE:
Multiomic Evidence of Coordinated Complex Rearrangements, Enhancer Hijacking, and Epigenomic Signatures in the First Whole-Chromosome-Phased Myeloma Genomes
ABSTRACT #: 3928 abs25-8959
FIRST AND PRESENTING AUTHOR: Nathan Becker, M.S.
LAST AUTHOR: Brian A. Walker, Ph.D.
PRESENTATION TITLE:
Individualized Treatment Risk Stratification Using Histopathology-Based Genomics Prediction in Multiple Myeloma: A Multicenter Study in 1429 Participants
ABSTRACT #: 4008 abs25-11635
FIRST AND PRESENTING AUTHOR: Arjun Raj Rajanna, M.S.
PRESENTATION TITLE:
A Phase 2 Trial of 89Zr-DFO-Daratumumab for CD38-Targeted Imaging of Multiple Myeloma (the iMMunoPET Study)
ABSTRACT #: 4052 abs25-10249
FIRST AND PRESENTING AUTHOR: C. Ola Landgren, M.D., Ph.D.
PRESENTATION TITLE:
Safety and Efficacy of Elranatamab + Nirogacestat in Patients with Relapsed or Refractory Multiple Myeloma: Results from the Phase 1b MagnetisMM-4 Study
ABSTRACT #: 4058 abs25-12198
FIRST AND PRESENTING AUTHOR: C. Ola Landgren, M.D., Ph.D.
PRESENTATION TITLE:
Assessment of Prolonged Thrombocytopenia After CD19 CAR-T Therapy: Evidence for Reduced Production
ABSTRACT #: 4157 abs25-10168
FIRST AND PRESENTING AUTHOR: Toral Shastri, D.O.
LAST AUTHOR: Denise Pereira, M.D.
PRESENTATION TITLE:
Optimizing Anticoagulation for Hospitalized Children: A Single-Institution Pediatric Anticoagulation Stewardship Experience
ABSTRACT #: 4381 abs25-1736
FIRST AND PRESENTING AUTHOR: Rachel Kronenfeld, M.D.
LAST AUTHOR: Fernando Corrales-Medina, M.D.
PRESENTATION TITLE:
Real-World Use of Prophylaxis in People with Non-Severe Hemophilia in the United States: Insights from the ATHN Transcends Study - Hemophilia Natural History Arm
ABSTRACT #: 4472 abs25-11755
FIRST AND PRESENTING AUTHOR: Fernando Corrales-Medina, M.D.
PRESENTATION TITLE:
Adherence to the 2018 World Cancer Research Fund/American Institute for Cancer Research Cancer Prevention Recommendations and Mortality Among Blood Cancer Survivors
ABSTRACT #: 4538 abs25-12470
FIRST AND PRESENTING AUTHOR: LaShae Rolle, M.P.H.
LAST AUTHOR: Tracy E. Crane, Ph.D.
PRESENTATION TITLE:
Feasibility and Preliminary Efficacy of a Mediterranean Diet and Home-Based Exercise Intervention During Chemotherapy for Lymphoma Survivors: The Life-L Study
ABSTRACT #: 4547 abs25-13243
FIRST AND PRESENTING AUTHOR: Melissa Lopez-Pentecost, Ph.D.
LAST AUTHOR: Craig H. Moskowitz, M.D.
PRESENTATION TITLE:
Clinical, Genetic, and Pathologic Differences Across Race, Ethnicity, and Sex in Patients with MDS and Precursor Conditions from the National MDS Natural History Study
ABSTRACT #: 3845 abs25-3862
LAST AUTHOR: Mikkael A. Sekeres, M.D., M.S.
PRESENTATION TITLE:
Biology of Circulating Tumor Cells (CTCs) in Multiple Myeloma (MM): Comparative Transcriptomic Profiling Reveals Egression-Associated Changes Related to CTC Burden
ABSTRACT #: 3927 abs25-8653
LAST AUTHOR: Tomas Jelinek, M.D.
PRESENTATION TITLE:
Understanding the Menopause Transition in Sickle Cell Disease: An Analysis of the Implementation of the Adapted Menopause Quick 6
ABSTRACT #: 4448 abs25-12813
LAST AUTHOR: Gelila Goba, M.D.
Reception
DATE/TIME: December 7, 9:00 P.M.
TITLE:
Miami Nights, Sylvester's Reception During ASH
LOCATION: LOEWS SAPPHIRE FALLS RESORT (Kingston Hall, 6601 Adventure Way, Orlando, FL 32819)
RSVP:
Sylvester.org/MiamiNights
Oral Presentations
DATE/TIME: December 8, 11:00 – 11:15 A.M.
PRESENTATION TITLE:
Preliminary Data from the Ongoing Phase 1 Study of the Menin-MLL Inhibitor Enzomenib (DSP-5336) in Combination with Venetoclax and Azacitidine in Patients with Relapsed or Refractory Acute Myeloid Leukemia
LOCATION: OCCC - Chapin Theater (W320)
ABSTRACT #: 765 abs25-2037
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
DATE/TIME: December 8, 3:30 – 3:45 P.M.
PRESENTATION TITLE:
Outcomes of T-cell/Histocyte-Rich Large B-cell Lymphoma (THRLBCL): An International LEO/MER and NiHiL Collaborative Study
LOCATION: OCCC - Tangerine Ballroom F3-4
ABSTRACT #: 898 abs25-11270
FIRST AND PRESENTING AUTHOR: Juan Pablo Alderuccio, M.D.
DATE/TIME: December 8, 4:00 – 4:15 P.M.
PRESENTATION TITLE:
Mismatching of Unrelated Donors Beyond a Single HLA-Locus Does Not Adversely Impact Outcomes at One Year Following Transplantation: Results from the NMDP Sponsored ACCESS Study
LOCATION: OCCC – W331
ABSTRACT #: 936 abs25-7189
LAST AND PRESENTING AUTHOR: Antonio Jimenez Jimenez, M.D.
DATE/TIME: December 8, 4:30 – 4:45 P.M.
PRESENTATION TITLE:
Mosunetuzumab and Polatuzumab Combined with Axicabtagene Ciloleucel Induce High Complete Response Rates at Day+90 in Relapsed/Refractory Large B-cell Lymphoma
LOCATION: OCCC - Tangerine Ballroom F3-4
ABSTRACT #: 1009 abs25-7701
FIRST AND PRESENTING AUTHOR: Jay Y. Spiegel, M.D.
Poster Presentations
DATE/TIME: December 8, 6:00 – 8:00 P.M.
LOCATION: OCCC - West Halls B3-B4
PRESENTATION TITLE:
Comparative Analysis of Prophylaxis with 1:1 Ratio pdVWF/FVIII Concentrate vs. Recombinant VWF in Type 3 von Willebrand Disease Adults in the United States: Clinical and Economic Perspective
ABSTRACT #: 4857 abs25-3817
PRESENTING AUTHOR: Fernando Corrales-Medina, M.D.
PRESENTATION TITLE:
PARP1 Facilitates Transcriptional Activity and Stability of the BCL6 Protein and Is a Therapeutic Target in BCL6 Expressing Lymphomas
ABSTRACT #: 5034 abs25-4326
FIRST AUTHOR: XiaoQing Lu
LAST AND PRESENTING AUTHOR: Izidore S. Lossos, M.D.
PRESENTATION TITLE:
A Dose Optimization Phase 1b/2 Study Evaluating Mipletamig (Formerly APVO436), a Novel Bispecific CD123 x CD3 ADAPTIR® Molecule in Combination Therapy for the Treatment of Frontline Acute Myeloid Leukemia (AML) in Patients Unfit for Intensive Chemotherapy
ABSTRACT #: 5198 abs25-7185
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
PRESENTATION TITLE:
INCB057643, a Bromodomain and Extra-Terminal Protein Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis: A Phase 1 Study of Safety and Efficacy
ABSTRACT #: 5574 abs25-4464
FIRST AND PRESENTING AUTHOR: Justin M. Watts, M.D.
PRESENTATION TITLE:
Exposure to Agent Orange and Risk of Myelodysplastic Syndromes
ABSTRACT #: 5626 abs25-3861
FIRST AND PRESENTING AUTHOR: Mikkael A. Sekeres, M.D., M.S.
PRESENTATION TITLE:
Real-World Treatment Patterns and Outcomes of First-Line Luspatercept in Patients with Myelodysplastic Syndromes in the United States
ABSTRACT #: 5638 abs25-10269
FIRST AND PRESENTING AUTHOR: Mikkael A. Sekeres, M.D., M.S.
PRESENTATION TITLE:
Cytogenetic Subgroup Analysis of the Advance Trial: A Randomized Multi-Center Study of Carfilzomib, Lenalidomide and Dexamethasone (KRd) with or Without Daratumumab (D) in Patients with Newly Diagnosed Multiple Myeloma (NDMM)
ABSTRACT #: 5763 abs25-8362
FIRST AND PRESENTING AUTHOR: Michael Durante, M.D., Ph.D.
LAST AUTHOR: C. Ola Landgren, M.D., Ph.D.
PRESENTATION TITLE:
A Phase 2 Trial of Teclistamab Plus Daratumumab Combination Therapy for High-Risk Smoldering Multiple Myeloma: First Pre-Planned Analysis (the REVIVE Study)
ABSTRACT #: 5775 abs25-10178
FIRST AND PRESENTING AUTHOR: C. Ola Landgren, M.D., Ph.D.
LAST AUTHOR: Dickran Kazandjian, M.D.
PRESENTATION TITLE:
Pre-Treatment CD19 Antigen Density and Multi-Antigen Profiling by Calibrated Quantitative Flow Cytometry Correlates with CAR T Efficacy in LBCL
ABSTRACT #: 5882 abs25-7716
FIRST AND PRESENTING AUTHOR: Jay Y. Spiegel, M.D.
PRESENTATION TITLE:
Real-World Use of Venetoclax and Hypomethylating Agents (HMA) in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Multi-Institutional Case Series
ABSTRACT #: 6401 abs25-10295
FIRST AND PRESENTING AUTHOR: Erica Lamkin, M.Sc.
LAST AUTHOR: Justin Taylor, M.D.
PRESENTATION TITLE:
Chromothripsis Drives High-Risk Multiple Myeloma by Copy Number Abnormalities and Rewiring the Epigenome to Activate Oncogenic Programs
ABSTRACT #: 5693 abs25-1694
LAST AUTHOR: Brian A. Walker, Ph.D.
PRESENTATION TITLE:
High-Dimensional Profiling Reveals Predominant Depletion of NK Cell Effector Phenotypes in Relapsed/Refractory Multiple Myeloma Patients Treated with Anti-CD38 Therapy
ABSTRACT #: 5720 abs25-13164
LAST AUTHOR: Tomas Jelinek, M.D.
PRESENTATION TITLE:
Longitudinal Immune Monitoring in Patients Treated with CD19 and BCMA CAR-T Cells Using Standardized 8-Color Flow Cytometry Panel Reveals Substantial Differences Among Products Kinetics and Persistence
ABSTRACT #: 5721 abs25-13274
LAST AUTHOR: Tomas Jelinek, M.D.
PRESENTATION TITLE:
Final Results of a Multi-Center Phase 2 Trial of Isatuximab-Lenalidomide in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
ABSTRACT #: 5834 abs25-10564
LAST AUTHOR: C. Ola Landgren, M.D., Ph.D.
Download Sylvester Impact Report